These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19773793)

  • 1. Acute coronary syndromes: oral factor Xa inhibitors in acute coronary syndromes.
    Tapp L; Wrigley B; Lip GY
    Nat Rev Cardiol; 2009 Oct; 6(10):619-20. PubMed ID: 19773793
    [No Abstract]   [Full Text] [Related]  

  • 2. Apixaban in acute coronary syndromes.
    Karthikeyan G; Eikelboom JW
    Cardiovasc Ther; 2011 Oct; 29(5):285-90. PubMed ID: 20553278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral factor Xa inhibitors for the long-term management of ACS.
    Wisler JW; Becker RC
    Nat Rev Cardiol; 2012 Feb; 9(7):392-401. PubMed ID: 22348973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants in acute coronary syndrome.
    Ahrens I; Bode C
    Semin Hematol; 2014 Apr; 51(2):147-51. PubMed ID: 24861799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
    Obonska K; Navarese EP; Lansky A; Tarantini G; Rossini R; Kozinski M; Musumeci G; Di Pasquale G; Górny B; Szczesniak A; Kowalewski M; Gurbel PA; Kubica J
    Atherosclerosis; 2013 Aug; 229(2):482-8. PubMed ID: 23672879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel oral anticoagulants in the treatment of acute coronary syndromes: is there any room for new anticoagulants?
    Deftereos S; Bouras G; Giannopoulos G; Kossyvakis C; Panagopoulou V; Pyrgakis V; Stefanadis C
    Curr Clin Pharmacol; 2012 Aug; 7(3):195-208. PubMed ID: 22564121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.
    Goldstein S; Bates ER; Bhatt DL; Cao C; Holmes D; Kupfer S; Martinez F; Spaeder J; Weitz JI; Ye Z; Zannad F;
    Thromb Haemost; 2014 Jun; 111(6):1141-52. PubMed ID: 24671450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding.
    Kohli P; Cannon CP
    Nat Rev Cardiol; 2011 Dec; 9(2):69-71. PubMed ID: 22182956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome: meta-analysis of randomized trials.
    Villablanca PA; Holmes D; Mohananey D; Briceno DF; Núñez Gil IJ; Kargoli F; Gupta T; Kizer JR; Bortnick AE; Wiley J; Menegus MA; Pyo R; García M; Ramakrishna H; Mookadam F
    Coron Artery Dis; 2017 Aug; 28(5):395-405. PubMed ID: 28328784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral anticoagulants after acute coronary syndromes.
    Wiggins NB; Granger CB; Alexander JH
    Cardiovasc Drugs Ther; 2012 Jun; 26(3):265-71. PubMed ID: 22434545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Return of Oral Anticoagulation in Chronic Stable Coronary Disease.
    Verheugt FWA
    Circulation; 2018 Apr; 137(16):1655-1657. PubMed ID: 29661947
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
    Spinthakis N; Farag M; Akhtar Z; Gorog DA
    Curr Vasc Pharmacol; 2018; 16(5):427-436. PubMed ID: 29345587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban, an oral direct factor Xa inhibitor.
    Piccini JP; Patel MR; Mahaffey KW; Fox KA; Califf RM
    Expert Opin Investig Drugs; 2008 Jun; 17(6):925-37. PubMed ID: 18491993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban in acute coronary syndromes--is it prime time?
    Asrar ul Haq M; van Gaal WJ
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reduction of haemorrhagic risk in acute coronary syndromes].
    Merino A; Roldán I; Marín F; Worner F;
    Med Clin (Barc); 2011 Nov; 137(14):650-5. PubMed ID: 20701931
    [No Abstract]   [Full Text] [Related]  

  • 17. Rear-view mirror observations on bleeding in acute coronary syndromes.
    Armstrong PW; Welsh RC
    JACC Cardiovasc Interv; 2010 Nov; 3(11):1178-80. PubMed ID: 21087754
    [No Abstract]   [Full Text] [Related]  

  • 18. The right oral antithrombotics in acute coronary syndromes.
    Grove EL; Storey RF
    Lancet; 2009 Dec; 374(9706):1947-8. PubMed ID: 20006120
    [No Abstract]   [Full Text] [Related]  

  • 19. Rivaroxaban in patients with a recent acute coronary syndrome.
    Mega JL; Braunwald E; Wiviott SD; Bassand JP; Bhatt DL; Bode C; Burton P; Cohen M; Cook-Bruns N; Fox KA; Goto S; Murphy SA; Plotnikov AN; Schneider D; Sun X; Verheugt FW; Gibson CM;
    N Engl J Med; 2012 Jan; 366(1):9-19. PubMed ID: 22077192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes.
    Gurbel PA; Tantry US
    Heart; 2016 Jun; 102(11):882-92. PubMed ID: 26944654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.